Prophylaxis of Macular Edema with Intravitreal Ranibizumab in Patients with Diabetic Retinopathy after Cataract Surgery: A Pilot Study

Table 2

Central-macular thickness at baseline compare to 1 and 3 months after the cataract surgery in both groups (including only patients that developed clinical significant macular edema (*CSME).

	Control group	Ranibizumab group
Patients CSME* at 1 month (%)	7 (25.92%)	1 (3.7%)
Patients CSME at 3 months (%)	6 (22.22%)	1 (3.7%)
CMT** Baseline (μm)	201.72±7.2	198
CMT at 1 month (μm)	315.7±36.8	312
CMT at 3 months (μm)	298.4±39.14	263

**CMT: central macular thickness in patients with macular edema. Not included measurements of all eyes.